After mulling over M&A options, Johnson & Johnson sprang into action in pursuit of Swiss biotech Actelion and initially received muted applause from investors.
The big news: Sanofi and its partner Regeneron received approval for the first PCSK9 inhibitor to come to market in the U.S.: Praluent. But Praluent’s sales to date haven’t awed analysts.
As Amgen executives continue to toast a spectacular 2015 performance — double-digit growth from five of eight blockbusters — CEO Robert Bradway has cast a keen eye on the biotech pioneer’s future.
